N
Nanjing Well Pharmaceutical Co Ltd
SSE:603351
Nanjing Well Pharmaceutical Co Ltd
SSE:603351
Price:
26.2
CNY
-1.47%
Market Closed
Market Cap:
¥3.5B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
N
|
Nanjing Well Pharmaceutical Co Ltd
SSE:603351
|
CN |
|
China Wuyi Co Ltd
SZSE:000797
|
CN |
Income Statement
Earnings Waterfall
Nanjing Well Pharmaceutical Co Ltd
Nanjing Well Pharmaceutical Co Ltd
Income Statement
Nanjing Well Pharmaceutical Co Ltd
Nanjing Well Pharmaceutical Co Ltd
Currency: CNY
| Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||
| Interest Expense |
8
|
9
|
10
|
11
|
12
|
14
|
15
|
14
|
16
|
16
|
15
|
14
|
14
|
0
|
0
|
|
| Revenue |
1 105
N/A
|
1 146
+4%
|
1 129
-1%
|
1 111
-2%
|
1 067
-4%
|
1 046
-2%
|
1 089
+4%
|
1 156
+6%
|
1 239
+7%
|
1 321
+7%
|
1 328
+0%
|
1 297
-2%
|
1 317
+2%
|
1 282
-3%
|
1 315
+3%
|
|
| Gross Profit | ||||||||||||||||
| Cost of Revenue |
(803)
|
(831)
|
(830)
|
(811)
|
(783)
|
(782)
|
(818)
|
(843)
|
(920)
|
(982)
|
(986)
|
(938)
|
(953)
|
(913)
|
(925)
|
|
| Gross Profit |
302
N/A
|
315
+4%
|
299
-5%
|
300
+0%
|
284
-5%
|
264
-7%
|
271
+2%
|
313
+16%
|
320
+2%
|
339
+6%
|
342
+1%
|
358
+5%
|
364
+2%
|
369
+1%
|
389
+6%
|
|
| Operating Income | ||||||||||||||||
| Operating Expenses |
(179)
|
(194)
|
(196)
|
(179)
|
(161)
|
(152)
|
(148)
|
(180)
|
(177)
|
(178)
|
(175)
|
(187)
|
(189)
|
(195)
|
(206)
|
|
| Selling, General & Administrative |
(137)
|
(149)
|
(154)
|
(117)
|
(108)
|
(99)
|
(91)
|
(115)
|
(122)
|
(121)
|
(118)
|
(111)
|
(116)
|
(118)
|
(123)
|
|
| Research & Development |
(43)
|
(46)
|
(44)
|
(47)
|
(56)
|
(55)
|
(57)
|
(47)
|
(58)
|
(62)
|
(63)
|
(60)
|
(74)
|
(79)
|
(85)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
(19)
|
0
|
0
|
0
|
(23)
|
0
|
0
|
0
|
(26)
|
0
|
0
|
0
|
|
| Other Operating Expenses |
1
|
1
|
2
|
4
|
3
|
2
|
0
|
5
|
3
|
4
|
6
|
10
|
1
|
2
|
2
|
|
| Operating Income |
124
N/A
|
120
-3%
|
103
-14%
|
121
+17%
|
124
+2%
|
112
-9%
|
123
+9%
|
133
+9%
|
142
+7%
|
161
+13%
|
167
+4%
|
172
+3%
|
175
+2%
|
174
0%
|
183
+5%
|
|
| Pre-Tax Income | ||||||||||||||||
| Interest Income Expense |
(7)
|
(7)
|
(8)
|
(8)
|
(11)
|
(12)
|
(14)
|
(11)
|
(11)
|
(1)
|
(0)
|
1
|
(0)
|
(11)
|
(6)
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
|
| Total Other Income |
(1)
|
(1)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Pre-Tax Income |
116
N/A
|
112
-4%
|
94
-16%
|
113
+20%
|
112
0%
|
100
-11%
|
109
+8%
|
121
+12%
|
131
+8%
|
160
+22%
|
166
+4%
|
172
+3%
|
174
+1%
|
163
-6%
|
177
+8%
|
|
| Net Income | ||||||||||||||||
| Tax Provision |
(15)
|
(8)
|
(0)
|
(18)
|
(19)
|
(14)
|
(15)
|
(12)
|
(14)
|
(25)
|
(22)
|
(27)
|
(27)
|
(25)
|
(31)
|
|
| Income from Continuing Operations |
101
|
103
|
94
|
94
|
93
|
87
|
93
|
109
|
117
|
135
|
144
|
145
|
147
|
139
|
146
|
|
| Income to Minority Interest |
2
|
2
|
2
|
1
|
1
|
1
|
2
|
3
|
3
|
3
|
3
|
1
|
1
|
1
|
2
|
|
| Net Income (Common) |
103
N/A
|
106
+3%
|
96
-9%
|
95
-1%
|
94
-1%
|
88
-7%
|
95
+8%
|
112
+18%
|
120
+7%
|
138
+14%
|
147
+7%
|
146
0%
|
148
+1%
|
140
-5%
|
148
+5%
|
|
| EPS (Diluted) |
0.77
N/A
|
0.8
+4%
|
0.69
-14%
|
0.71
+3%
|
0.7
-1%
|
0.65
-7%
|
0.67
+3%
|
0.83
+24%
|
0.89
+7%
|
1.02
+15%
|
1.1
+8%
|
1.08
-2%
|
1.09
+1%
|
1.03
-6%
|
1.07
+4%
|
|
Switch to:
Switch to:
See Also
Discover More
